# Pomalyst (pomalidomide) PDUFA date and FDA approval status

Canonical: https://sec-api.dev/pdufa/pomalidomide

> The next catalyst for Pomalyst (pomalidomide), sponsored by BRISTOL MYERS SQUIBB CO (BMY), is its topline data readout, Jan to Apr 2027.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: exact day, quarter only, month only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Key facts

| Field | Value |
| --- | --- |
| Drug | Pomalyst (pomalidomide) |
| Codes |  |
| Sponsor | BRISTOL MYERS SQUIBB CO (BMY) https://sec-api.dev/companies/bmy/catalysts |
| Indications | [Multiple Myeloma](https://sec-api.dev/indications/multiple-myeloma), [Relapsed or Refractory Multiple Myeloma (RRMM)](https://sec-api.dev/indications/relapsed-or-refractory-multiple-myeloma-rrmm), [Relapsed or Refractory Multiple Myeloma](https://sec-api.dev/indications/relapsed-or-refractory-multiple-myeloma) |
| Modality |  |
| FDA designations | priority review |

## Timeline

### May 14, 2020: label expansion decision

- Status: completed, approved. Date confidence: exact.
- First seen 2026-11-12T03:48:32.313Z, last confirmed 2026-11-16T22:20:01.192Z.
- openFDA Drugs@FDA: "NDA204026 SUPPL-23 (Efficacy): submission_status AP, submission_status_date 20200514, review_priority PRIORITY; sponsor_name BRISTOL; product POMALYST (POMALIDOMIDE)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA204026%22
- openFDA Drugs@FDA: "NDA204026 SUPPL-24 (Efficacy): submission_status AP, submission_status_date 20200514, review_priority PRIORITY; sponsor_name BRISTOL; product POMALYST (POMALIDOMIDE)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA204026%22

### November 20, 2020: label expansion decision

- Status: completed, approved. Date confidence: exact.
- First seen 2026-11-12T03:48:32.313Z, last confirmed 2026-11-16T22:20:01.192Z.
- openFDA Drugs@FDA: "NDA204026 SUPPL-27 (Efficacy): submission_status AP, submission_status_date 20201120, review_priority PRIORITY; sponsor_name BRISTOL; product POMALYST (POMALIDOMIDE)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA204026%22

### April 13, 2026: primary completion

- Status: completed. Date confidence: exact. Stage: 3. Indication: Multiple Myeloma.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT03651128 (Efficacy and Safety Study of bb2121 Versus Standard Regimens in Subjects With Relapsed and Refractory Multiple Myeloma (RRMM)): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2026-04-13 (ACTUAL); Lead Sponsor Celgene." https://clinicaltrials.gov/study/NCT03651128

### Jan to Apr 2027: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 3. Indication: Relapsed or Refractory Multiple Myeloma.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT05519085 (A Study to Evaluate Mezigdomide, Bortezomib and Dexamethasone (MEZIVd) Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM)): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2027-01-10 (ESTIMATED); Lead Sponsor Celgene." https://clinicaltrials.gov/study/NCT05519085

### January 2027: primary completion

- Status: scheduled. Date confidence: month. Stage: 3. Indication: Relapsed or Refractory Multiple Myeloma.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT05519085 (A Study to Evaluate Mezigdomide, Bortezomib and Dexamethasone (MEZIVd) Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM)): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2027-01-10 (ESTIMATED); Lead Sponsor Celgene." https://clinicaltrials.gov/study/NCT05519085

### Dec 2027 to Mar 2028: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 3. Indication: Relapsed or Refractory Multiple Myeloma (RRMM).
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT06615479 (A Study to Compare the Efficacy and Safety of BMS-986393 Versus Standard Regimens in Adult Participants With Relapsed or Refractory and Lenalidomide-exposed Multiple Myeloma (QUINTESSENTIAL-2)): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2027-12-30 (ESTIMATED); Lead Sponsor Juno Therapeutics, Inc., a Bristol-Myers Squibb Company." https://clinicaltrials.gov/study/NCT06615479

### December 2027: primary completion

- Status: scheduled. Date confidence: month. Stage: 3. Indication: Relapsed or Refractory Multiple Myeloma (RRMM).
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT06615479 (A Study to Compare the Efficacy and Safety of BMS-986393 Versus Standard Regimens in Adult Participants With Relapsed or Refractory and Lenalidomide-exposed Multiple Myeloma (QUINTESSENTIAL-2)): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2027-12-30 (ESTIMATED); Lead Sponsor Juno Therapeutics, Inc., a Bristol-Myers Squibb Company." https://clinicaltrials.gov/study/NCT06615479

## Same indication

- [Anitocabtagene autoleucel](https://sec-api.dev/pdufa/anitocabtagene-autoleucel) (GILD)
- [Arlocabtagene autoleucel](https://sec-api.dev/pdufa/arlocabtagene-autoleucel) (BMY)
- [BB2121](https://sec-api.dev/pdufa/bb2121) (BMY)
- [Belantamab mafodotin](https://sec-api.dev/pdufa/belantamab-mafodotin) (GSK)
- [Cemsidomide](https://sec-api.dev/pdufa/cemsidomide) (CCCC)
- [Cilta-cel](https://sec-api.dev/pdufa/cilta-cel) (JNJ)
- [DARZALEX (daratumumab)](https://sec-api.dev/pdufa/daratumumab) (JNJ)
- [Empliciti (elotuzumab)](https://sec-api.dev/pdufa/elotuzumab) (BMY)
- [Elrexfio (elranatamab)](https://sec-api.dev/pdufa/elranatamab) (PFE)
- [Etentamig](https://sec-api.dev/pdufa/etentamig) (ABBV)
- [Zenbexus (iberdomide hydrochloride)](https://sec-api.dev/pdufa/iberdomide) (BMY)
- [ABECMA (idecabtagene vicleucel)](https://sec-api.dev/pdufa/idecabtagene-vicleucel) (BMY)
- [Igi, 10%](https://sec-api.dev/pdufa/igi-10) (TAK)
- [JNJ-79635322](https://sec-api.dev/pdufa/jnj-79635322) (JNJ)
- [Revlimid® (lenalidomide)](https://sec-api.dev/pdufa/lenalidomide) (JNJ)
- [PHE885](https://sec-api.dev/pdufa/phe885) (NVS)
- [Ramantamig](https://sec-api.dev/pdufa/ramantamig) (JNJ)
- [Talquetamab](https://sec-api.dev/pdufa/talquetamab) (JNJ)
- [TECVAYLI (teclistamab)](https://sec-api.dev/pdufa/teclistamab) (JNJ)
- [Venclexta (venetoclax)](https://sec-api.dev/pdufa/venetoclax) (ABBV)

Calendar months: [January 2027](https://sec-api.dev/fda-calendar/2027-01), [December 2027](https://sec-api.dev/fda-calendar/2027-12)

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/pdufa/pomalidomide.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "Pomalyst (pomalidomide) PDUFA date and FDA approval status." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/pdufa/pomalidomide

```bibtex
@misc{secapidev_pdufa_pomalidomide_20261116,
  title        = {Pomalyst (pomalidomide) PDUFA date and FDA approval status},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/pdufa/pomalidomide}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_pdufa_pomalidomide_20261116","title":"Pomalyst (pomalidomide) PDUFA date and FDA approval status","publisher":"sec-api.dev","URL":"https://sec-api.dev/pdufa/pomalidomide","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
